 407-412 (1996) 
Introduction
The thalidomide tragedy in the early 1960s brought about a worldwide realization that drugs, pesticides, and other chemical substances have the potential to induce damage in the unborn child. This was followed by the introduction of new guidelines for preclinical testing requirements. Naturally, interest focused mainly on structural abnormalities, and testing strategies were devised that were expected to detect and characterize prenatal insults leading to gross morphological changes in the embryo and fetus. Although experience has shown that terata occur only rarely compared with other end points of developmental toxicity, such as effects on growth and viability, the attitude that malformations are all important still persists with many investigators and regulatory agency reviewers.
As early as 1963, a fourth area of concern, behavioral teratology, was introduced in a review by Werboff and Gottlieb (1) on the postnatal effects of prenatal X-irradiation and exposure to psychoactive drugs. However, regulatory action was not taken until 1975 when Great Britain and Japan incorporated requirements for developmental neurotoxicity testing into their respective guidelines for testing of medicinal products for reproductive toxicity. At this time, the relevance to humans of the potential of chemicals to induce damage to the central nervous system following prenatal exposure and exposure during childhood had become widely accepted based on the data that were available for organic mercury, lead, and alcohol. Although no validated methods were available, it was felt that early detection of a substance's potential for developmental neurotoxicity in animal experiments could prevent widespread exposure of pregnant women and thereby minimize or eliminate the risk for the growing and developing child. It was assumed that, for an unknown compound, where no clues about the possible localization of a potential lesion existed, functional tests might give greater sensitivity than histopathological and biochemical methods. The underlying biological mechanisms could then be elucidated by secondary studies from the functional changes observed in first-pass testing. Based on this rationale, testing of drugs for end points of developmental neurotoxicity commenced in the mid-1970s, but it was not until the early 1980s that behavioral testing batteries became established as routine tests in the pharmaceutical industry.
Since that time a large amount of data on tests and test combinations for medicinal products has accumulated in the archives of regulatory agencies and pharmaceutical companies, data that should be reexamined critically with the aim of identifying methods that may be recommended.
Developmental Neurotoxicity within the Framework of Regulatory Studies
It was clear from the beginning that, for therapeutic agents, neurobehavioral toxicity testing would have to be incorporated into existing study designs for the detection of any (adverse) effect on development. These would have to be adapted to allow the collection of information on functional changes, in addition to the data on viablity, growth, and gross structural abnormalities of conceptus and offspring (2) . Regulatory studies for developmental toxicity do not detect these different end points equally well. They can be considered fairly sensitive for effects on viablity and general growth parameters (body weight); however, when the emphasis is placed on rare events like malformations, a study size of usually 10 to 20 pregnant animals per group will always be insufficient in picking up any but the strongest effects. Also, the different variables constituting an embryofetotoxic effect do not usually occur with an even distribution within and between litters of a dose group. Some litters may be free of any relevant findings, others may contain only one or a few affected fetuses or pups, or, alternatively, the whole litter may be abnormal. unexpected, it will be necessary to study end points for developmental neurotoxicity with all substances for which exposure of the embryo, the fetus, the newborn, the child, and the juvenile cannot be excluded definitely. Unlike malformations that can only be induced during a narrow time window in organogenesis, functional changes can be expected to occur during this differentiation phase and, additionally, for as long a period as the organ system needs to attain full functional competence. For detection of such effects, animals will have to be exposed during embryo-fetal development and postnatally through puberty. Observation, however, will have to continue for a longer time period, ideally to old age, to make sure that delayed manifestations are not overlooked. None of the study designs currently recommended by guidelines includes effects that may become apparent only in aging animals, e.g., premature onset of senescence or, with respect to CNS function, senility.
Animal Species
Rabbits, rats, and mice are the animal species primarily used in routine developmental toxicity testing; however, the potential of inducing neurobehavioral toxicity in the offspring is evaluated almost exclusively in rats (Table 1 ). This is due to the fact that regulatory agencies have accepted data from rats in cases in which this species proved to be an unsuitable animal model for the substance under study when they should have encouraged the use of another animal species. This practice reveals astonishing insights into how great an importance is attached to possible effects with postnatal manifestations in humans (including neurobehavioral findings) during the process of hazard identification and risk assessment. At present, we are making the world safer for rats. But how secure can we feel about the detection of hazards for the developing nervous system when this animal model is not even reasonably close to humans? Even if we do not yet know how changes in animal behavior may translate to the situation in humans, the least we can do is to use the most appropriate animal model available to us, i.e., that closest to humans with respect to metabolism, pharmacokinetics, pharmacodynamics, and physiology. If such a species cannot be found or used, we should consider conducting studies in more than one animal species. This has been standard procedure in the testing for structural abnormalities and still is, despite intellectual acknowledgement that one relevant species is better than two or more less suitable ones. If we want to increase the predictability of animal results for humans, it will be necessary to develop methods for species other (14) , and brain biochemistry (15, 16 A simple water maze, for example, which is part of many routine testing batteries, will be used to collect data on learning ability and memory. The parameters recorded routinely are whether the animal is successful within the time limit, the number of errors made, and the time needed to escape from the maze. Experience shows that most (all?) animals will learn the route that takes them to the exit easily once they have managed to discover (or have been shown) where it is situated. Probably this is not a very sensitive test for the detection of subtle differences in learning/memory functions, as the performance of rats is quite variable even in control groups, and the demands on the central nervous system of this simple task do not seem to be high enough to bring out clear effects on learning ability when brain damage is slight. In addition, the way the test is applied and evaluated, often only as a measure of learning, does not make use of its full potential. The first trial, in which the naive animal has no due about the location of the exit, more often than not is treated as a training run, and, therefore, is not considered for further analysis of (learning) behavior. In a study report, the reviewer will be told how many animals failed to reach the exit in time, but the reasons why they failed to do so are never described. If (Table 7) . WhAether this is due to a true were antibiotic drugs. Since the effects ing up effects at low doses, maybe overly so, sex-specific action of the compound canwere not expected, this shows the necessity but for a detection study this would not be not be decided, as studies for secondary of conducting developmental neurotoxicity considered a disadvantage. Other tests and characterization are usually performed tests for all substances to which the devel-parameters that showed significant changes only if malformations are encountered in oping human will be exposed.
at low doses are active and passive avoidance the routine studies, not for a suspected Table 6 . Behavioral tests giving positive results in detection studies for therapeutic agents.
